Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread over the world since its emergence. Although the dominant route of SARS-CoV-2 infection is respiratory, a number of studies revealed infection risk from contaminated surfaces and products, including porcine-derived food and other products. The SARS-CoV-2 outbreak has been severely threatening public health, and disrupting porcine products trade and the pig industry. Swine acute diarrhea syndrome coronavirus (SADS-CoV), which was responsible for large-scale, fatal disease in piglets, emerged in 2017 and has caused enormous economic losses in the pig industry. Currently, reverse transcription real-time PCR (RT-rPCR) is the gold standard method for SARS-CoV-2 diagnosis and is most commonly used for SADS-CoV detection. However, inaccurate detection of the SARS-CoV-2 infection obtained by RT-rPCR is increasingly reported, especially in specimens with low viral load. This study aimed to develop an accurate reverse transcription droplet digital PCR (RT-ddPCR) assay for the detection of SARS-CoV-2 and SADS-CoV simultaneously. Two pairs of primers and one double-quenched probe targeting the RNA-dependent RNA polymerase (RDRP) region of the open reading frame 1ab (ORF1ab) gene of SARS-CoV-2 and the corresponding ORF1ab region of SADS-CoV were designed to develop the RT-ddPCR assay. The sensitivity, specificity, repeatability, and reproducibility were tested using complementary RNAs (cRNAs) and clinical specimens. The detection limits of RT-ddPCR were 1.48 ± 0.18 and 1.38 ± 0.17 copies in a 20 μL reaction for SARS-CoV-2 and SADS-CoV cRNAs, respectively (n = 8), showing approximately 4- and 10-fold greater sensitivity than the RT-rPCR assay. This assay also exhibited good specificity, repeatability, and reproducibility. The established RT-ddPCR assay was shown to be a highly effective, accurate, and reliable method for the sensitive detection of SARS-CoV-2 and SADS-CoV. This RT-ddPCR assay could be used to detect both SARS-CoV-2 and SADS-CoV in a sample with one double-quenched probe, and is also the first reported RT‐ddPCR assay for SADS-CoV detection.
Akabane virus (AKAV) is a Culicoides-borne Orthobunyavirus that is teratogenic to the fetus of cattle and small ruminant species. This study aimed to develop an effective diagnostic assay for the detection of AKAV using produced monoclonal antibody (mAb). Firstly, the mAb against N protein of AKAV was produced and characterized by western blot (WB) and indirect immunofluorescence (IFA) assays. Then, the linear epitope of AKAV N protein against the mAb was identified and the mAb was applied to establish a double antibody sandwich ELISA (DAS-ELISA). One AKAV N-reactive monoclonal mAb was generated and designated as 2D3. WB and IFA assays indicated that 2D3 could react with both recombinant N protein and AKAV isolate TJ2016. The linear epitope recognized by mAb 2D3 was located at amino acids 168–182 of AKAV N protein. The double antibody sandwich ELISA (DAS-ELISA) established based mAb 2D3 was able to detect both the purified AKAV N protein (with detection limit of 6.25 ng/ml) and AKAV-infected cell culture supernatant (with detection limit of 250 TCID50/ml). Taken together, we successfully prepared a mAb 2D3 against AKAV N protein and identified its corresponding linear epitope, and then established a DAS-ELISA for the detection of AKAV antigen. A produced mAb against AKAV N protein was used to define a linear epitope of AKAV and establish a DAS-ELISA for AKAV antigen detection.
Background: Peste des petits ruminants (PPR) is a highly contagious and economically devastating disease affecting sheep and goats. The performance and cost of serological diagnostic kits remain a major challenge for PPR eradication. Objective: The nucleocapsid (N) protein of PPR virus and its monoclonal antibody (mAb) were engineered for development of a blocking ELISA. Methods: The N protein was truncated and expressed by the eukaryotic expression system. The mAb 65A8 was recovered, followed by sequencing and cloning of its variable regions into expression vector. The recombinant mAb was expressed in 293F cells. Key characteristics of the recombinant mAb were evaluated. A blocking ELISA was developed and validated. Comparison between the blocking ELISA and a commercial blocking ELISA kit was performed. Results: The truncated N protein exhibited a higher yield compared to the full-length N protein. Recombinant mAb 65A8 demonstrated the same blocking efficacy as that of ascites-derived mAb. The yield of recombinant mAb reached 5.3 mg/100 mL. The affinity constant of recombinant mAb 65A8 was comparable to that of the ascites-derived 65A8 (3.48 × 109 L/mol versus 6.76 × 109 L/mol). Based on the truncated N and recombinant mAb, a blocking ELISA was established. The detection limit of blocking ELISA was 1:128 and 1:32 based on strong positive serum and weak positive serum, respectively. Inter- and intra-assay coefficients of variation were <10%, indicating robust reproducibility. The blocking ELISA kit showed high coincidence with the commercial ELISA kit recommended by the World Organization for Animal Health reference laboratory. Conclusions: This study successfully developed a reliable and cost-effective blocking ELISA by protein engineering of the antigen and mAb. Highlights: The mAb of PPR Virus was recombinantly expressed in 239F cells, which was employed in the development of a reliable blocking ELISA. This work provided novel ideas and methods for the development of the blocking ELISA kits.